JFG
RANI icon

Jefferies Financial Group’s Rani Therapeutics RANI Stock Holding History

Jefferies Financial Group’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.3K Sell
22,221
-7,649
-26% -$9.77K ﹤0.01% 1679
2025
Q4 		$40.3K Buy
+29,870
New +$45.1K ﹤0.01% 1771

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Jefferies Financial Group's RANI Position: Q1 2026 in Review

Jefferies Financial Group reduced its Rani Therapeutics (RANI) stake by 26% in Q1 2026, selling an estimated $9.77K and leaving 22,221 shares worth $16.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1679.

Jefferies Financial Group first reported a position in RANI in Q4 2025 and has held it in 2 quarters since. The position peaked at $40.3K in Q4 2025. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Jefferies Financial Group held 22,221 shares of Rani Therapeutics worth $16.3K as of Q1 2026.
  • Jefferies Financial Group sold 7,649 Rani Therapeutics shares in Q1 2026, an estimated $9.77K.
  • Rani Therapeutics made up ﹤0.01% of Jefferies Financial Group's portfolio in Q1 2026, its #1679 holding.
  • Jefferies Financial Group first reported a position in Rani Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Jefferies Financial Group's Rani Therapeutics position peaked at $40.3K in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.